PE20021155A1 - Derivados de quinolina como antagonistas de neuropeptidos y - Google Patents
Derivados de quinolina como antagonistas de neuropeptidos yInfo
- Publication number
- PE20021155A1 PE20021155A1 PE2002000425A PE2002000425A PE20021155A1 PE 20021155 A1 PE20021155 A1 PE 20021155A1 PE 2002000425 A PE2002000425 A PE 2002000425A PE 2002000425 A PE2002000425 A PE 2002000425A PE 20021155 A1 PE20021155 A1 PE 20021155A1
- Authority
- PE
- Peru
- Prior art keywords
- alkyl
- alcoxy
- pyrrolidin
- methyl
- quinoline
- Prior art date
Links
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical class N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 title abstract 2
- 239000005557 antagonist Substances 0.000 title abstract 2
- 229940027991 antiseptic and disinfectant quinoline derivative Drugs 0.000 title abstract 2
- 108090000189 Neuropeptides Proteins 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- -1 3-METHOXY-BENZYLOXY Chemical class 0.000 abstract 1
- 208000030814 Eating disease Diseases 0.000 abstract 1
- 208000019454 Feeding and Eating disease Diseases 0.000 abstract 1
- 229940127470 Lipase Inhibitors Drugs 0.000 abstract 1
- 102000028517 Neuropeptide receptor Human genes 0.000 abstract 1
- 108070000018 Neuropeptide receptor Proteins 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 150000003973 alkyl amines Chemical class 0.000 abstract 1
- MDFFNEOEWAXZRQ-UHFFFAOYSA-N aminyl Chemical compound [NH2] MDFFNEOEWAXZRQ-UHFFFAOYSA-N 0.000 abstract 1
- 206010003246 arthritis Diseases 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 235000014632 disordered eating Nutrition 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical class [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- AHLBNYSZXLDEJQ-FWEHEUNISA-N orlistat Chemical compound CCCCCCCCCCC[C@H](OC(=O)[C@H](CC(C)C)NC=O)C[C@@H]1OC(=O)[C@H]1CCCCCC AHLBNYSZXLDEJQ-FWEHEUNISA-N 0.000 abstract 1
- 229960001243 orlistat Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
- C07D215/42—Nitrogen atoms attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Diabetes (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Endocrinology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Quinoline Compounds (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP01112370 | 2001-05-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20021155A1 true PE20021155A1 (es) | 2002-12-17 |
Family
ID=8177497
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2002000425A PE20021155A1 (es) | 2001-05-21 | 2002-05-17 | Derivados de quinolina como antagonistas de neuropeptidos y |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US6818767B2 (enExample) |
| EP (1) | EP1395564B1 (enExample) |
| JP (1) | JP3715280B2 (enExample) |
| KR (1) | KR100621287B1 (enExample) |
| CN (1) | CN100376557C (enExample) |
| AR (1) | AR035979A1 (enExample) |
| AT (1) | ATE387428T1 (enExample) |
| AU (1) | AU2002338896B2 (enExample) |
| BR (1) | BR0209957A (enExample) |
| CA (1) | CA2446324A1 (enExample) |
| DE (1) | DE60225274T2 (enExample) |
| ES (1) | ES2300478T3 (enExample) |
| GT (1) | GT200200090A (enExample) |
| MX (1) | MXPA03010565A (enExample) |
| PA (1) | PA8545301A1 (enExample) |
| PE (1) | PE20021155A1 (enExample) |
| UY (1) | UY27300A1 (enExample) |
| WO (1) | WO2002094789A1 (enExample) |
| ZA (1) | ZA200308783B (enExample) |
Families Citing this family (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6900226B2 (en) * | 2000-09-06 | 2005-05-31 | Hoffman-La Roche Inc. | Neuropeptide Y antagonists |
| AU2002352878B2 (en) * | 2001-11-27 | 2007-11-22 | Merck Sharp & Dohme Corp. | 2-Aminoquinoline compounds |
| PL372295A1 (en) * | 2002-02-04 | 2005-07-11 | F.Hoffmann-La Roche Ag | Quinoline derivatives as npy antagonists |
| US7105526B2 (en) | 2002-06-28 | 2006-09-12 | Banyu Pharmaceuticals Co., Ltd. | Benzimidazole derivatives |
| CA2489251A1 (en) | 2002-07-05 | 2004-01-15 | F. Hoffmann-La Roche Ag | Quinazoline derivatives |
| AU2003253364B2 (en) | 2002-08-07 | 2007-06-07 | F. Hoffmann-La Roche Ag | Thiazole derivatives |
| US7772188B2 (en) | 2003-01-28 | 2010-08-10 | Ironwood Pharmaceuticals, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
| MXPA05009722A (es) * | 2003-03-10 | 2006-03-09 | Schering Corp | Inhibidores heterociclicos de cinasa: metodos de uso y sintesis. |
| WO2005028438A1 (ja) | 2003-09-22 | 2005-03-31 | Banyu Pharmaceutical Co., Ltd. | 新規ピペリジン誘導体 |
| CA2545340A1 (en) | 2003-11-10 | 2005-05-26 | Synta Pharmaceuticals, Corp. | Fused heterocyclic compounds |
| US20080125403A1 (en) | 2004-04-02 | 2008-05-29 | Merck & Co., Inc. | Method of Treating Men with Metabolic and Anthropometric Disorders |
| US20060183763A1 (en) * | 2004-12-31 | 2006-08-17 | Pfizer Inc | Novel pyrrolidyl derivatives of heteroaromatic compounds |
| EP1892241B1 (en) | 2005-05-30 | 2016-03-30 | Msd K.K. | Novel piperidine derivative |
| EP1916239A4 (en) | 2005-08-10 | 2009-10-21 | Banyu Pharma Co Ltd | PYRIDOLVERBINDUNG |
| US7875633B2 (en) | 2005-08-24 | 2011-01-25 | Banyu Pharmaceutical Co., Ltd. | Phenylpyridone derivative |
| WO2007029847A1 (ja) | 2005-09-07 | 2007-03-15 | Banyu Pharmaceutical Co., Ltd. | 二環性芳香族置換ピリドン誘導体 |
| AU2006307046A1 (en) | 2005-10-27 | 2007-05-03 | Msd K.K. | Novel benzoxathiin derivative |
| RU2428423C2 (ru) | 2005-11-10 | 2011-09-10 | Баниу Фармасьютикал Ко., Лтд. | Азазамещенные спиропроизводные |
| WO2008020302A2 (en) * | 2006-08-17 | 2008-02-21 | Pfizer Products Inc. | Heteroaromatic quinoline-based compounds as phosphodiesterase (pde) inhibitors |
| EP2072519A4 (en) | 2006-09-28 | 2009-10-21 | Banyu Pharma Co Ltd | DIARYLKETIMINDERIVAT |
| AU2008233662B2 (en) | 2007-04-02 | 2012-08-23 | Msd K.K. | Indoledione derivative |
| WO2008141077A1 (en) * | 2007-05-10 | 2008-11-20 | Janssen Pharmaceutica N.V. | Process for the preparation of tetrahydroquinolinyl, benzoxazine and benzothiazine derivatives |
| US8759348B2 (en) * | 2007-05-17 | 2014-06-24 | Helperby Therapeutics Limited | Use of 4-(pyrrolidin-1-yl)quinoline compounds to kill clinically latent microorganisms |
| WO2008150940A1 (en) * | 2007-06-01 | 2008-12-11 | E. I. Du Pont De Nemours And Company | Chrysenes for green luminescent applications |
| US8969514B2 (en) | 2007-06-04 | 2015-03-03 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases |
| WO2008151257A2 (en) | 2007-06-04 | 2008-12-11 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
| SI2220076T1 (sl) * | 2007-11-15 | 2012-05-31 | Gilead Sciences Inc | Inhibitorji replikacije virusa humane imunske pomankljivosti |
| US8354429B2 (en) | 2007-11-16 | 2013-01-15 | Gilead Sciences, Inc. | Inhibitors of human immunodeficiency virus replication |
| AU2009220605A1 (en) | 2008-03-06 | 2009-09-11 | Msd K.K. | Alkylaminopyridine derivative |
| CA2717384A1 (en) | 2008-03-28 | 2009-10-01 | Banyu Pharmaceutical Co., Ltd. | Diarylmethylamide derivative having melanin-concentrating hormone receptor antagonism |
| ES2627848T3 (es) | 2008-06-04 | 2017-07-31 | Synergy Pharmaceuticals Inc. | Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos |
| AU2009261248A1 (en) | 2008-06-19 | 2009-12-23 | Banyu Pharmaceutical Co., Ltd. | Spirodiamine-diarylketoxime derivative |
| ES2624828T3 (es) | 2008-07-16 | 2017-07-17 | Synergy Pharmaceuticals Inc. | Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros |
| US20110124674A1 (en) | 2008-07-30 | 2011-05-26 | Hiroyuki Kishino | 5/5-or 5/6-membered condensed ring cycloalkylamine derivative |
| US8410284B2 (en) | 2008-10-22 | 2013-04-02 | Merck Sharp & Dohme Corp | Cyclic benzimidazole derivatives useful as anti-diabetic agents |
| WO2010051206A1 (en) | 2008-10-31 | 2010-05-06 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
| JP2013520502A (ja) | 2010-02-25 | 2013-06-06 | メルク・シャープ・エンド・ドーム・コーポレイション | 有用な抗糖尿病薬である新規な環状ベンズイミダゾール誘導体 |
| US9616097B2 (en) | 2010-09-15 | 2017-04-11 | Synergy Pharmaceuticals, Inc. | Formulations of guanylate cyclase C agonists and methods of use |
| CA2826649C (en) | 2011-02-25 | 2016-07-26 | Merck Sharp & Dohme Corp. | Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents |
| US20140045746A1 (en) | 2012-08-02 | 2014-02-13 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
| JP2016516004A (ja) | 2013-02-22 | 2016-06-02 | メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． | 抗糖尿病二環式化合物 |
| WO2014139388A1 (en) | 2013-03-14 | 2014-09-18 | Merck Sharp & Dohme Corp. | Novel indole derivatives useful as anti-diabetic agents |
| US9708367B2 (en) | 2013-03-15 | 2017-07-18 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase and their uses |
| EP2968439A2 (en) | 2013-03-15 | 2016-01-20 | Synergy Pharmaceuticals Inc. | Compositions useful for the treatment of gastrointestinal disorders |
| PL3004138T3 (pl) | 2013-06-05 | 2024-07-29 | Bausch Health Ireland Limited | Ultra-oczyszczeni agoniści peptydowi cyklazy guanylanowej C, sposób ich uzyskiwania i ich zastosowanie |
| WO2015051496A1 (en) | 2013-10-08 | 2015-04-16 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
| WO2018106518A1 (en) | 2016-12-06 | 2018-06-14 | Merck Sharp & Dohme Corp. | Antidiabetic heterocyclic compounds |
| WO2018118670A1 (en) | 2016-12-20 | 2018-06-28 | Merck Sharp & Dohme Corp. | Antidiabetic spirochroman compounds |
| ES3002968T3 (en) | 2017-07-14 | 2025-03-10 | Innate Tumor Immunity Inc | Nlrp3 modulators |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| LU43730A1 (enExample) * | 1962-06-14 | 1963-07-13 | ||
| US3272824A (en) * | 1962-12-06 | 1966-09-13 | Norwich Pharma Co | 4-amino-6, 7-di(lower) alkoxyquinolines |
| US3812127A (en) * | 1966-10-31 | 1974-05-21 | Pfizer | 4-(quinolin-4-yl)piperazine-1-carboxylic acid esters |
| US4035367A (en) * | 1974-09-09 | 1977-07-12 | Sandoz, Inc. | Hydroxyalkyl-substituted-amino-quinolines |
| CA1247547A (en) | 1983-06-22 | 1988-12-28 | Paul Hadvary | Leucine derivatives |
| CA1270837A (en) | 1984-12-21 | 1990-06-26 | Hoffmann-La Roche Limited | Oxetanones |
| CA1328881C (en) | 1984-12-21 | 1994-04-26 | Pierre Barbier | Process for the manufacture of oxetanones |
| AU641215B2 (en) | 1990-02-13 | 1993-09-16 | Merrell Dow Pharmaceuticals Inc. | Stabilized sulfonate, sulfate, phosphonate and phosphate derivatives of hirudin |
| US5274143A (en) | 1991-07-23 | 1993-12-28 | Hoffmann-La Roche Inc. | Process for the preparation of (R)-3-hexyl-5,6-dihydro-4-hydroxy-6-undecyl-2H-pyran-2-one and (R)-5,6-dihydro-6-undecyl-2H-pyran-2,4(3H)-dione |
| AU719392B2 (en) * | 1996-10-01 | 2000-05-11 | Kyowa Hakko Kirin Co., Ltd. | Nitrogen-containing heterocyclic compounds |
| US6004996A (en) | 1997-02-05 | 1999-12-21 | Hoffman-La Roche Inc. | Tetrahydrolipstatin containing compositions |
| US6267952B1 (en) | 1998-01-09 | 2001-07-31 | Geltex Pharmaceuticals, Inc. | Lipase inhibiting polymers |
| CA2340056C (en) | 1998-08-14 | 2007-01-09 | F. Hoffmann-La Roche Ag | Pharmaceutical compositions containing lipase inhibitors |
| PT1105123E (pt) | 1998-08-14 | 2004-08-31 | Hoffmann La Roche | Composicoes farmaceuticas contendo inibidores da lipase e quitosano |
| WO2001034764A2 (en) * | 1999-11-08 | 2001-05-17 | Cytion S.A. | Apparatus and methods for positioning and analyzing biological membranous objects |
| US6900226B2 (en) * | 2000-09-06 | 2005-05-31 | Hoffman-La Roche Inc. | Neuropeptide Y antagonists |
-
2002
- 2002-05-08 AU AU2002338896A patent/AU2002338896B2/en not_active Ceased
- 2002-05-08 KR KR1020037015121A patent/KR100621287B1/ko not_active Expired - Fee Related
- 2002-05-08 CA CA002446324A patent/CA2446324A1/en not_active Abandoned
- 2002-05-08 ES ES02771639T patent/ES2300478T3/es not_active Expired - Lifetime
- 2002-05-08 CN CNB028104013A patent/CN100376557C/zh not_active Expired - Fee Related
- 2002-05-08 AT AT02771639T patent/ATE387428T1/de not_active IP Right Cessation
- 2002-05-08 JP JP2002591462A patent/JP3715280B2/ja not_active Expired - Fee Related
- 2002-05-08 MX MXPA03010565A patent/MXPA03010565A/es active IP Right Grant
- 2002-05-08 DE DE60225274T patent/DE60225274T2/de not_active Expired - Fee Related
- 2002-05-08 EP EP02771639A patent/EP1395564B1/en not_active Expired - Lifetime
- 2002-05-08 WO PCT/EP2002/005120 patent/WO2002094789A1/en not_active Ceased
- 2002-05-08 BR BR0209957-8A patent/BR0209957A/pt not_active IP Right Cessation
- 2002-05-16 PA PA20028545301A patent/PA8545301A1/es unknown
- 2002-05-17 PE PE2002000425A patent/PE20021155A1/es not_active Application Discontinuation
- 2002-05-17 AR ARP020101836A patent/AR035979A1/es not_active Application Discontinuation
- 2002-05-20 US US10/151,505 patent/US6818767B2/en not_active Expired - Fee Related
- 2002-05-20 GT GT200200090A patent/GT200200090A/es unknown
- 2002-05-21 UY UY27300A patent/UY27300A1/es not_active Application Discontinuation
-
2003
- 2003-11-11 ZA ZA200308783A patent/ZA200308783B/en unknown
-
2004
- 2004-05-24 US US10/852,509 patent/US20050049413A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| AR035979A1 (es) | 2004-07-28 |
| JP3715280B2 (ja) | 2005-11-09 |
| AU2002338896B2 (en) | 2006-04-27 |
| ZA200308783B (en) | 2005-02-11 |
| EP1395564B1 (en) | 2008-02-27 |
| US6818767B2 (en) | 2004-11-16 |
| CN100376557C (zh) | 2008-03-26 |
| JP2004536066A (ja) | 2004-12-02 |
| UY27300A1 (es) | 2002-11-29 |
| WO2002094789A1 (en) | 2002-11-28 |
| CN1522249A (zh) | 2004-08-18 |
| KR100621287B1 (ko) | 2006-09-13 |
| ES2300478T3 (es) | 2008-06-16 |
| US20020198194A1 (en) | 2002-12-26 |
| US20050049413A1 (en) | 2005-03-03 |
| EP1395564A1 (en) | 2004-03-10 |
| CA2446324A1 (en) | 2002-11-28 |
| PA8545301A1 (es) | 2003-01-24 |
| DE60225274D1 (de) | 2008-04-10 |
| BR0209957A (pt) | 2004-03-30 |
| MXPA03010565A (es) | 2004-03-02 |
| GT200200090A (es) | 2003-06-19 |
| KR20030096416A (ko) | 2003-12-24 |
| ATE387428T1 (de) | 2008-03-15 |
| DE60225274T2 (de) | 2009-03-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20030471A1 (es) | Compuesto de imidazopiridin como moduladores del receptor 5-ht4 | |
| PE20020366A1 (es) | Derivados de piperazina como ligandos del receptor 5ht2 | |
| PE20030739A1 (es) | Antagonistas del receptor de adenosina a2a | |
| PE20020735A1 (es) | Derivados de quinazolona como antagonistas de receptores adrenergicos alfa-1a/b | |
| PE20020667A1 (es) | Derivados de piperazina como ligandos del receptor 5ht2 | |
| PE20011084A1 (es) | Derivados de quinolina como antagonistas alfa-2 | |
| PE20010854A1 (es) | USO DE DERIVADOS DE PIRIMIDINA 4 SUSTITUIDOS COMO ANTAGONISTAS DE LOS RECEPTORES DE GLUTAMATO mGluR1 | |
| PE20010039A1 (es) | Derivados de esteres del acido carbamico como agonistas y/o antagonistas del receptor metabotropico del glutamato | |
| PE20060401A1 (es) | Derivados de n-(2-bencil)-2-fenil-butanamidas y propanamidas como moduladores del receptor de androgeno | |
| PE20001467A1 (es) | Derivados de 4-fenilpiridina como antagonistas del receptor de neuroquinina | |
| PE20011030A1 (es) | Combinaciones farmaceuticas que comprenden tegaserod y omeprazol | |
| PE20011294A1 (es) | Composiciones farmaceuticas de agonistas/antagonistas de estrogeno y estatinas para tratar la osteoporosis y reducir el colesterol | |
| PE20011265A1 (es) | Novedosos derivados diamino sustituidos | |
| CL2003002050A1 (es) | Compuestos derivados de 1-piperazin-1,2-dihidroindeno, su composicion farmaceutica y el uso de esta para tratar enfermedades del sistema nervioso central. | |
| PE20040840A1 (es) | Derivados de 4-oxoquinolina como inhibidores de la integrasa del vih | |
| PE20050465A1 (es) | Compuestos derivados de quinuclidina como antagonistas del receptor muscarinico m3 | |
| HUP0301573A2 (hu) | Szubsztituált arilpirazinok, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk | |
| PE20051039A1 (es) | [1,8] naftiridin-2-onas y compuestos relacionados | |
| PE20040758A1 (es) | Compuestos 3-aminopirazoles n-sustituidos como inhibidores de la enzima tirosin-quinasa asociada al receptor pdgf y procedimientos para su preparacion | |
| CY1105688T1 (el) | Κυανοπυρρολες ως αγωνιστες υποδοχεων προγεστερονης | |
| PE20040593A1 (es) | DERIVADOS DE DIHIDROPIRIMIDO[4,5-d]PIRIMIDONA AMINO SUSTITUIDOS COMO INHIBIDORES DE TIROSINACINASAS DEL GRUPO SRC | |
| PE20021005A1 (es) | Quinazolinas como inhibidores de mmp-13 | |
| PE20050420A1 (es) | Fenacilo 2-hidroxi-3-diaminoalcanos | |
| PE20060689A1 (es) | Derivados de sulfonamidas como antagonistas de receptores orexina 2 | |
| PE20030603A1 (es) | Derivados de quinolina |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |